The US Food and Drug Administration has officially approved AbbVie's EMBLAVEO™ (aztreonam and avibactam) as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination...
atai Life Sciences, a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, has officially announced positive topline results from Beckley...